Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.


Market Cap$115.2B

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals, Inc.29.90%-8.8-

Earnings Call Q1 2024

May 2, 2024 - AI Summary

Regeneron reported solid financial results for the first quarter of 2024, with revenues growing 7% (excluding COVID antibody contributions) driven by strong sales growth from Dupixent and Libtayo.
Dupixent continues to perform well, with global net sales growing 25% YoY to $3.1 billion in Q1. The drug is the clear leader in new-to-brand prescription share across all FDA-approved indications and leads in total biologic prescriptions in four indications.
EYLEA HD, Regeneron's treatment for retinal diseases, had a successful launch, outperforming expectations. U.S. net sales grew 63% sequentially to $200 million in Q1, positioning it as the new standard of care in the market.

Exclusive for Stockcircle Pro members

Sign upSign Up

Target Price by Analysts

10% upsideRegeneron Pharmaceuticals Target Price DetailsTarget Price

Current Fair Value

128.9% upside

Undervalued by 128.9% based on the discounted cash flow analysis.

Share Statistics

Market cap$115.20 Billion
Enterprise Value-
Dividend Yield$0.0 (0.0%)
Earnings per Share$33.85
Outstanding Shares107,943,750
Avg 30 Day Volume482,543


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio29.86
Price to Sales8.77
Price to Book Ratio-
Enterprise Value to Revenue-
Enterprise Value to EBIT-
Enterprise Value to Net Income0
Total Debt to Enterprise-
Debt to Equity-

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Regeneron Pharmaceuticals, Inc.

CEO: Leonard Schleifer